Certara to sell regulatory and medical writing unit to Veristat for up to $135 million
Certara agreed on April 21, 2026 to sell its global medical writing and related regulatory services business to Veristat for $100 million in cash, plus up to $35 million in earn-out payments tied to the business's performance after closing. The company expects the sale to close in the second quarter of 2026 and plans to update its 2026 guidance at that time, so shareholders will not see the sale's full effect on guidance until then.
Key points
- Cash consideration of $100 million, subject to post-closing adjustments for working capital, indebtedness and transaction expenses
- Up to $35 million in contingent earn-out payments based on the business's financial performance after closing
- Up to $15 million of the closing payment may be held in escrow if certain items are not satisfied at closing
- The business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025; closing is expected in the second quarter of 2026
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 22, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.